李建军 张志明

[摘要] 目的 通過检测健脾化瘀方治疗后脾虚血瘀型原发性肝癌（PLC）患者甲胎蛋白（AFP）、糖类抗原19-9（CA19-9）、癌胚抗原（CEA）含量的变化及体力状况（KPS）评分、生活质量（QOL）评分的变化，研究健脾化瘀方对脾虚血瘀型PLC患者的作用。 方法 选取天水市中医医院2018年10月至2020年12月就诊的脾虚血瘀型PLC患者80例，采用随机对照的方法分为两组，即治疗组（n=40）、对照组（n=40），对照组给予榄香烯及化疗药行肝动脉栓塞术治疗，治疗组在对照组基础上给予口服健脾化瘀方联合榄香烯及化疗药行肝动脉栓塞术治疗1个月。观察治疗前后患者肿瘤标记物AFP、CA19-9、CEA的含量及KPS评分、QOL评分。 结果 两组患者治疗后AFP、CA19-9、CEA含量均低于本组治疗前，差异有统计学意义（P<0.05），治疗组患者治疗后KPS评分及QOL评分均高于本组治疗前，差异有统计学意义（P<0.05），对照组患者治疗后QOL评分均高于本组治疗前，差异有统计学意义（P<0.05）。治疗组患者治疗后AFP、CA19-9、CEA含量均低于对照组，差异有统计学意义（P<0.05），KPS评分及QOL评分均高于对照组，差异有统计学意义（P<0.05）。 结论 健脾化瘀方可以降低脾虚血瘀型PLC患者AFP、CA19-9、CEA的含量，可以升高KPS评分及QOL评分，从而起到治疗PLC的作用，并提高患者生活质量。

[关键词] 原发性肝癌;健脾化瘀方;AFP;CA19-9;CEA;KPS;QOL

[中图分类号] R735.7          [文献标识码] A          [文章编号] 1673-9701（2021）35-0009-04

Effect of Jianpi Huayu Prescription on AFP， CA19-9， CEA， KPS and QOL scores in patients with primary liver cancer of spleen deficiency and blood stasis type

LI Jianjun1   ZHANG Zhiming2

1.Department of Oncology， Tianshui Hospital of Traditional Chinese Medicine in Gansu Province， Tianshui   741000， China; 2.Department of Oncology， Affiliated Hospital of Gansu University of Traditional Chinese Medicine， Lanzhou   730000， China

[Abstract] Objective To study the effect of Jianpi Huayu Prescription on patients with primary liver cancer （PLC） of spleen deficiency and blood stasis type by detecting the changes of alpha fetoprotein（AFP）， carbohydrate antigen 19-9 （CA19-9） and carcinoembryonic antigen （CEA）， as well as the changes of performance status （KPS） score and quality of life （QOL） score. Methods A total of 80 patients with PLC of the spleen deficiency and blood stasis type who were treated in Tianshui Hospital of Traditional Chinese Medicine from October 2018 to December 2020 were selected and divided into two groups by the randomized control method， namely the treatment group（n=40） and the control group（n=40）. The control group was treated with hepatic artery embolization using elemene and chemotherapy drugs， and the treatment group was treated with oral Jianpi Huayu Prescription combined with hepatic artery embolization using elemene and chemotherapy drugs for 1 month on the basis of the control group. The contents of AFP， CA19-9， CEA， and KPS score and QOL score of the patients were observed before and after treatment. Results After treatment， the AFP， CA19-9 and CEA contents of patients in the 2 groups were lower than before， and the differences were statistically significant（P<0.05）; the KPS scores and QOL scores of patients in the treatment group were higher than before， and the differences were statistically significant （P<0.05）; the QOL scores of patients in control group were higher than before， and the differences were statistically significant （P<0.05）. After treatment， AFP， CA19-9 and CEA contents in the treatment group were lower than those in the control group， and the differences were statistically significant （P<0.05）; the KPS score and QOL score were higher than those in the control group， and the differences were statistically significant （P<0.05）. Conclusion Jianpi Huayu Prescription can reduce the contents of AFP， CA19-9 and CEA in PLC patients with spleen deficiency and blood stasis， and can increase the KPS score and QOL score， thus playing a role in treating PLC and improving the quality of life of patients.

[Key words] Primary liver cancer; Jianpi Huayu Prescription; AFP; CA19-9; CEA; KPS; QOL

原发性肝癌（Primary liver cancer，PLC）是我国常见恶性肿瘤之一，其发病隐匿，预后不佳，每年我国因肝癌死亡的人数约有11万，约占全世界肝癌死亡人数的一半[1]。基于对PLC患者中医辨治规律的数据挖掘研究表明，脾虚血瘀型患者居多。天水市中……